Keanna Wolcott
Adult Health · Spokane, WANPI 1750085908
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 61.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $729 and has fallen 55.3% since, to $325 in 2025.
Across 23 payments — averaging $53.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$753
- AstraZeneca$237
- Lilly USA, LLC$88
- Lundbeck LLC$45
- Amgen$35
- Biogen$24
- plus $46 from 3 others
What the payments were for
- Food & beverage$1,227100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $753 |
| AstraZeneca(2 entities) | 3 | $237 |
| Lilly USA, LLC | 1 | $88 |
| Lundbeck LLC | 3 | $45 |
| Amgen | 2 | $35 |
| Biogen | 1 | $24 |
| Merck | 1 | $16 |
| GSK | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,227 in reported general payments places this provider in the 75th percentile of 252 adult health providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methenamine Hippurate | 12 | $669 |
| Baclofen | 17 | $398 |
| Levothyroxine Sodium | 14 | $213 |
| Quetiapine Fumarate | 15 | $191 |
| Trazodone Hcl | 13 | $190 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 11 | $105 |
| Furosemide | 17 | $104 |
| Gabapentin | 12 | $103 |
| Tramadol Hcl | 11 | $92 |
Paid to pharmacies, not to this prescriber.
Other adult health in Spokane
- Anneke van SlotenSpokane$2K
- Jonathan WarrenSpokane$2K
- George BaxterSeattle$868K
- April WatkinsSeattle$101K
- Ming Chi HsiaoTacoma$46K
- Leslie SwansonSeattle$18K
- Kindra Clark-SnustadSeattle$10K
- Amanda NortonBellevue$8K
- Alexxia RichmondSnohomish$7K
- Jonathan TurowskiMill Creek$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.